Elzonris (tagraxofusp-erzs) vs Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
Elzonris (tagraxofusp-erzs) vs Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn)
Elzonris (tagraxofusp-erzs) is a targeted therapy specifically approved for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare type of blood cancer, and works by targeting and binding to a protein on the surface of cancer cells, delivering a toxic payload that kills them. Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), on the other hand, is an asparagine-specific enzyme used as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and is designed to deplete the amino acid asparagine, which certain leukemia cells require to survive. The choice between the two would depend on the specific type of blood cancer a patient has; Elzonris is for BPDCN, while Rylaze is for ALL, and they are not interchangeable.
Difference between Elzonris and Rylaze
| Metric | Elzonris (tagraxofusp-erzs) | Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) |
|---|---|---|
| Generic name | Tagraxofusp-erzs | Asparaginase erwinia chrysanthemi (recombinant)-rywn |
| Indications | Blastic plasmacytoid dendritic cell neoplasm (BPDCN) | Acute lymphoblastic leukemia (ALL), Lymphoblastic lymphoma |
| Mechanism of action | CD123-directed cytotoxin | Enzyme that breaks down asparagine, depriving tumor cells of an essential amino acid |
| Brand names | Elzonris | Rylaze |
| Administrative route | Intravenous | Intramuscular |
| Side effects | Capillary leak syndrome, fever, fatigue, nausea | Hypersensitivity reactions, pancreatitis, abnormal liver tests, nausea, musculoskeletal pain |
| Contraindications | Hypersensitivity to tagraxofusp-erzs or any of its components | Hypersensitivity to asparaginase or any of its components |
| Drug class | CD123-directed cytotoxin | Asparagine specific enzyme |
| Manufacturer | Stemline Therapeutics, Inc. | Jazz Pharmaceuticals, Inc. |
Efficacy
Elzonris (tagraxofusp-erzs) Efficacy in Treating Leukemia
Elzonris (tagraxofusp-erzs) is a targeted therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients aged 2 years and older. BPDCN is a rare and aggressive form of leukemia. Clinical trials have demonstrated the efficacy of Elzonris in this patient population. In a pivotal trial, Elzonris showed a clinically meaningful response rate with some patients achieving complete remission. The treatment has been considered a significant advancement for BPDCN, as it is the first therapy specifically indicated for this condition.
Elzonris works by targeting and binding to the interleukin-3 receptor (CD123), which is overexpressed on the surface of BPDCN cells, and delivers a cytotoxic agent directly to the cancer cells. The efficacy of Elzonris in the treatment of other forms of leukemia beyond BPDCN has not been established, and its use in such conditions would be considered off-label.
Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) Efficacy in Treating Leukemia
Rylaze, also known as asparaginase erwinia chrysanthemi (recombinant)-rywn, is an asparagine-specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients who have developed hypersensitivity to E. coli-derived asparaginase. Rylaze has been shown to maintain asparaginase activity levels in patients who are unable to continue with E. coli-derived asparaginase due to allergic reactions.
The efficacy of Rylaze was established in a clinical trial that measured the proportion of patients who achieved and maintained a certain threshold of asparaginase activity, which is believed to be associated with improved treatment outcomes in ALL and LBL. The results demonstrated that Rylaze effectively sustained the therapeutic levels of asparaginase activity required for the treatment of these leukemias. Its use is crucial for patients who have limited treatment options due to their hypersensitivity to other asparaginase products.
Regulatory Agency Approvals
Elzonris
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Rylaze
-
Food and Drug Administration (FDA), USA
Access Elzonris or Rylaze today
If Elzonris or Rylaze are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us